Implications of diabetes mellitus on pathophysiology of Tuberculosis: Role of AGE-RAGE Axis and Glycated Proteins
Sudhasini PandaiD, Alankrita SinghiD, Diravya M SeelaniD, Alisha AroraiD, Gunjan Dagar, Abdul Samath EthayathullaiD, Kalpana LuthraiD, Anant MohaniD, Naval K. VikramiD, Neeraj Kumar GuptaiD, Mayank SinghiD, Archana SinghiD
Abstract
Chronic hyperglycemia in diabetes mellitus promotes the formation of advanced glycation end products (AGEs) via non-enzymatic glycation of plasma proteins. AGEs and their receptor RAGE are central to diabetic complications, as they activate inflammatory pathways and oxidative stress. We studied the AGE-RAGE axis in uncontrolled diabetic individuals having pulmonary TB (PTB+DM), uncontrolled diabetic individuals with no infection (DM), and pulmonary TB patients (PTB). Levels of AGEs and RAGE were measured across these groups and compared to controls. The results showed significantly higher AGEs and RAGE levels in the diabetic milieu, reflecting chronic hyperglycemia. These AGEs were shown to be associated with impaired macrophage function, evidenced by reduced phagocytic capacity. Increased AGEs correlated with disease severity in tuberculosis patients co-affected by diabetes, indicating compromised immune responses. RAGE expression also showed a higher trend in TB patients, although not statistically significant, potentially influencing infection outcomes. Glycated calmodulin was also elevated in diabetic and TB-diabetes comorbid patients and negatively correlated with nitric oxide (NO) levels, suggesting that calmodulin glycation hinders NO production in diabetic conditions. Molecular dynamic studies revealed that glycosylation disrupts calmodulins interaction with inducible nitric oxide synthase (iNOS), potentially explaining the decreased NO levels in TB-diabetes comorbid patients. These findings underscore the detrimental impact of AGEs and RAGE in diabetic immune dysregulation, highlighting the need for therapeutic strategies to mitigate their effects on macrophage function and restore immune responses. HighlightsO_LIWe conducted this study to examine how hyperglycemia-driven AGEs and RAGE contribute to immune dysfunction and disease severity in diabetic and TB-diabetes patients. C_LIO_LIHigh AGEs and RAGE impairs macrophage function, decreasing phagocytic capacity and worsening disease severity in TB-diabetes comorbidity. C_LIO_LIGlycosylation disrupts calmodulins interaction with iNOS, contributing to lower NO levels and weakened immune responses in TB-diabetes comorbidity. C_LIO_LIThe AGE-RAGE axis should be studied further for these comorbid conditions to assess and improve macrophage function and restore immune responses. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Chronic hyperglycemia drives alterations in macrophage effector function in pulmonary tuberculosis
S. Panda, D. M. Seelan, … A. Singh·bioRxiv·Jan 18, 2022
- Macrophages of diabetes and tuberculosis co-morbid conditions show perturbed differentiation and metabolic signatures
Nidhi Raj Yadav, Nikhil Bhalla, … Ranjan Kumar Nanda·bioRxiv·Mar 5, 2025
- A blunted GPR183/oxysterol axis during dysglycemia results in delayed recruitment of macrophages to the lung during M. tuberculosis infection
M. D. Ngo, S. Bartlett, … K. Ronacher·bioRxiv·Jan 5, 2022
- Pre-diabetes increases tuberculosis disease severity, while high body fat without impaired glucose tolerance is protective
R. Sinha, M. D. Ngo, … K. Ronacher·bioRxiv·Apr 6, 2021
- Genetic and pharmacologic modulation of RAGE rescues the diabetes-mediated impairments to bone at multiple length scales
Kaitlyn S. Broz, Timothy Hung, … S. Y. Tang·bioRxiv·Apr 6, 2026
- Single-cell profiling of the lung immune cells of diabetes-tuberculosis comorbidity reveals reduced type-II interferon and elevated Th17 responses.
Shweta Chaudhary, Mothe Sravya, … Ranjan Kumar Nanda·bioRxiv·Oct 24, 2024